SADR Gengle™ - a Database Inheriting Google® Technology in Presenting Genes Responsible for Serious Adverse Drug Reactions

Search Where =

Stevens-Johnson Syndrome



Pathway Foreground Gene Count & Ratio Background Gene Count & Ratio p-value q-value
Cytokine-cytokine receptor interaction 91 / 21.56% 275 / 3.42% 1.52E-40 2.21E-38
ErbB signaling pathway 45 / 10.66% 84 / 1.05% 7.44E-27 5.43E-25
Cellular antigens 92 / 21.80% 480 / 5.98% 3.03E-25 1.47E-23
Natural killer cell mediated cytotoxicity 52 / 12.32% 142 / 1.77% 9.92E-25 3.62E-23
Cytokines 63 / 14.93% 229 / 2.85% 3.35E-24 8.85E-23
Prostate cancer 43 / 10.19% 90 / 1.12% 3.64E-24 8.85E-23
Pancreatic cancer 38 / 9.00% 69 / 0.86% 3.93E-23 8.19E-22
Toll-like receptor signaling pathway 43 / 10.19% 103 / 1.28% 2.39E-22 4.36E-21
T cell receptor signaling pathway 39 / 9.24% 89 / 1.11% 6.04E-21 9.79E-20
MAPK signaling pathway 62 / 14.69% 277 / 3.45% 7.32E-20 1.07E-18
Chronic myeloid leukemia 34 / 8.06% 72 / 0.90% 3.49E-19 4.63E-18
Colorectal cancer 36 / 8.53% 86 / 1.07% 6.78E-19 8.25E-18
Antigen processing and presentation 36 / 8.53% 88 / 1.10% 1.23E-18 1.38E-17
Focal adhesion 51 / 12.09% 199 / 2.48% 1.47E-18 1.53E-17
Renal cell carcinoma 32 / 7.58% 67 / 0.83% 3.12E-18 3.03E-17
Bladder cancer 26 / 6.16% 40 / 0.50% 1.75E-17 1.60E-16
Glioma 30 / 7.11% 64 / 0.80% 5.46E-17 4.69E-16
Type I diabetes mellitus 26 / 6.16% 44 / 0.55% 9.82E-17 7.97E-16
Endometrial cancer 25 / 5.92% 51 / 0.63% 1.06E-14 8.11E-14
Fc epsilon RI signaling pathway 28 / 6.64% 70 / 0.87% 1.50E-14 1.10E-13
Apoptosis 30 / 7.11% 88 / 1.10% 5.30E-14 3.68E-13
Non-small cell lung cancer 24 / 5.69% 53 / 0.66% 1.42E-13 9.43E-13
Melanoma 26 / 6.16% 71 / 0.88% 7.04E-13 4.47E-12
Epithelial cell signaling in Helicobacter pylori infection 25 / 5.92% 65 / 0.81% 8.16E-13 4.97E-12
Acute myeloid leukemia 22 / 5.21% 54 / 0.67% 8.00E-12 4.67E-11
Adipocytokine signaling pathway 22 / 5.21% 68 / 0.85% 3.06E-10 1.72E-09
Hematopoietic cell lineage 23 / 5.45% 81 / 1.01% 1.02E-09 5.54E-09
B cell receptor signaling pathway 21 / 4.98% 69 / 0.86% 1.96E-09 1.02E-08
Jak-STAT signaling pathway 19 / 4.50% 56 / 0.70% 2.66E-09 1.34E-08
Adherens junction 21 / 4.98% 72 / 0.90% 3.71E-09 1.81E-08
Insulin signaling pathway 28 / 6.64% 132 / 1.64% 4.53E-09 2.13E-08
VEGF signaling pathway 20 / 4.74% 67 / 0.83% 6.32E-09 2.88E-08
Protein kinases 57 / 13.51% 463 / 5.76% 9.82E-09 4.34E-08
Small cell lung cancer 21 / 4.98% 85 / 1.06% 4.37E-08 1.88E-07
mTOR signaling pathway 16 / 3.79% 48 / 0.60% 5.99E-08 2.50E-07
Regulation of actin cytoskeleton 32 / 7.58% 213 / 2.65% 4.80E-07 1.95E-06
GnRH signaling pathway 20 / 4.74% 94 / 1.17% 7.30E-07 2.88E-06
TGF-beta signaling pathway 19 / 4.50% 87 / 1.08% 9.87E-07 3.79E-06
Metabolism of xenobiotics by cytochrome P450 17 / 4.03% 70 / 0.87% 1.05E-06 3.94E-06
Type II diabetes mellitus 13 / 3.08% 41 / 0.51% 1.69E-06 6.16E-06
Cell adhesion molecules (CAMs) 33 / 7.82% 242 / 3.01% 2.21E-06 7.85E-06
Thyroid Cancer 11 / 2.61% 29 / 0.36% 2.62E-06 9.09E-06
Progesterone-mediated oocyte maturation 19 / 4.50% 103 / 1.28% 8.63E-06 2.93E-05
CAM ligands 22 / 5.21% 152 / 1.89% 5.07E-05 1.68E-04
Complement and coagulation cascades 14 / 3.32% 69 / 0.86% 5.38E-05 1.75E-04
Leukocyte transendothelial migration 18 / 4.27% 113 / 1.41% 8.27E-05 2.62E-04
Renin - angiotensin system 7 / 1.66% 17 / 0.21% 1.21E-04 3.77E-04
Gap junction 16 / 3.79% 98 / 1.22% 1.58E-04 4.82E-04
Long-term potentiation 13 / 3.08% 69 / 0.86% 1.90E-04 5.65E-04
Axon guidance 18 / 4.27% 127 / 1.58% 3.05E-04 8.91E-04
Glutathione metabolism 9 / 2.13% 39 / 0.49% 5.21E-04 1.49E-03
Dorso-ventral axis formation 7 / 1.66% 24 / 0.30% 6.80E-04 1.89E-03
Wnt signaling pathway 19 / 4.50% 149 / 1.86% 6.87E-04 1.89E-03
Cell cycle 16 / 3.79% 115 / 1.43% 7.80E-04 2.11E-03
Cytochrome P450 10 / 2.37% 52 / 0.65% 8.99E-04 2.39E-03
Huntington's disease 7 / 1.66% 29 / 0.36% 1.74E-03 4.54E-03
Dentatorubropallidoluysian atrophy (DRPLA) 5 / 1.18% 14 / 0.17% 1.97E-03 5.04E-03
Long-term depression 11 / 2.61% 76 / 0.95% 3.83E-03 9.63E-03
p53 signaling pathway 10 / 2.37% 65 / 0.81% 3.89E-03 9.63E-03
Linoleic acid metabolism 6 / 1.42% 31 / 0.39% 9.30E-03 2.26E-02
Melanogenesis 12 / 2.84% 101 / 1.26% 1.05E-02 2.51E-02
Caffeine metabolism 3 / 0.71% 7 / 0.09% 1.14E-02 2.68E-02
Regulation of autophagy 6 / 1.42% 34 / 0.42% 1.35E-02 3.14E-02
Trinitrotoluene degradation 2 / 0.47% 2 / 0.02% 1.39E-02 3.18E-02

Query Genes


Cytokine-cytokine receptor interaction IL6R;  IL19;  FLT1;  IL1R1;  IL1A;  FLT4;  KDR;  IL2RA;  IL2;  TNFRSF11B;  TNFRSF25;  TGFBR1;  IL23A;  TGFB3;  TGFB2;  CCL5;  TNF;  MET;  IL3;  IL2RG;  IL4R;  IL5;  IL23R;  IL4;  IL6;  PDGFRB;  TNFSF11;  PDGFB;  PDGFA;  CXCL12;  TNFRSF1B;  TNFRSF1A;  IL21;  CCR3;  LTA;  IL6ST;  IL18RAP;  IL18R1;  CCR6;  CCR2;  IL10;  IL10RA;  IL10RB;  IL11;  OSM;  CSF2;  FIGF;  CSF1;  LTB;  IL24;  VEGFC;  VEGFB;  VEGFA;  IL12B;  IL12A;  IL13RA1;  IL13;  CXCR4;  IL1R2;  IFNB1;  EPO;  IFNG;  IFNGR1;  IL20;  BMP7;  BMP2;  CCL17;  TGFB1;  CCL20;  IL15;  IL18;  IL17A;  PGF;  IFNA16;  CCL4;  IFNA7;  IFNGR2;  IFNA2;  CD40LG;  IFNA1;  CCL2;  CCL3;  LIF;  CD40;  TNFRSF10A;  TNFSF8;  TNFRSF8;  FASLG;  FAS;  EGFR;  EGF;  
ErbB signaling pathway FRAP1;  HBEGF;  PIK3CG;  PIK3R1;  MAP2K2;  MAP2K1;  MAPK9;  PLCG1;  PTK2;  TGFA;  ABL1;  ABL2;  GRB2;  GAB1;  MAP2K4;  ARAF;  NRG1;  AKT1;  NCK1;  AKT2;  CRK;  GSK3B;  BRAF;  HRAS;  EGFR;  RAF1;  EGF;  MYC;  JUN;  SRC;  CDKN1A;  MAPK3;  PRKCA;  MAPK8;  SOS1;  SHC1;  CBL;  ERBB3;  ELK1;  KRAS;  BTC;  NCK2;  ERBB2;  AREG;  ERBB4;  
Cellular antigens IL1R1;  HLA-DRA;  HLA-DRB1;  HLA-DRB4;  HLA-DRB5;  IL2RA;  HLA-DRB3;  TNFRSF11B;  F3;  TNFRSF25;  SELP;  IGF1R;  ICOS;  CDH1;  SELE;  HLA-E;  INSR;  IL2RG;  IL4R;  GYPA;  CD9;  CD4;  CD8A;  PDGFRB;  CCR6;  TNFSF11;  ITGA5;  TNFRSF1B;  TNFRSF1A;  ITGA3;  IL6R;  IL6ST;  IL18RAP;  IL18R1;  CD151;  CCR2;  CCR3;  IL10RA;  IL10RB;  ADAM10;  MAPK14;  IL13RA1;  KDR;  IL13RA2;  CXCR4;  IL1R2;  GZMB;  TLR1;  TLR2;  CD74;  ACE;  ITGB3;  FCGR1A;  IFNGR1;  TLR3;  VCAM1;  NRP1;  MICB;  MICA;  TBX21;  FCGR2B;  FCGR2A;  ITGB1;  CD44;  FCGR3B;  FCGR3A;  CD46;  ITGAV;  MET;  ENG;  CD40LG;  CD40;  HLA-DMA;  HLA-DMB;  HLA-A;  HLA-B;  HLA-C;  ABCG2;  FOXP3;  ADAM17;  TNFRSF10A;  HLA-DQB1;  HLA-DQA2;  HLA-DQA1;  TNFSF8;  TNFRSF8;  CD28;  FASLG;  FAS;  NOD2;  TLR8;  BSG;  
Natural killer cell mediated cytotoxicity HLA-C;  PTK2B;  KIR2DL3;  KIR2DS2;  KIR2DS1;  KIR2DL2;  IFNGR2;  MAP2K2;  MAP2K1;  IFNA16;  KIR3DL1;  PLCG1;  GZMB;  IFNA1;  IFNB1;  GRB2;  NFATC1;  HLA-A;  IFNG;  IFNGR1;  VAV2;  ARAF;  PIK3CG;  PIK3R1;  MICB;  MICA;  LCK;  FCGR3A;  RAF1;  NFATC2;  HLA-E;  CASP3;  TNF;  KIR2DL1;  PTPN6;  TNFRSF10A;  CSF2;  MAPK3;  FCGR3B;  PRKCA;  IFNA7;  SOS1;  SHC1;  IFNA2;  FASLG;  FAS;  KRAS;  HRAS;  BRAF;  RAC1;  HLA-B;  FYN;  
Cytokines IL12B;  IL12A;  IL6;  IL19;  IL13;  TNFSF11;  PDGFB;  PDGFA;  CXCL12;  IL1F10;  CCL4;  IL1RN;  IFNA1;  IL21;  IFNB1;  IL1A;  CCL2;  EPO;  CCL3;  IFNG;  LTA;  IL2;  IFNA16;  IL20;  BMP7;  BMP2;  LIF;  NRG1;  CCL17;  FGF2;  ANGPT2;  ANGPT1;  TGFB1;  CCL20;  CD40LG;  IL15;  IL18;  IL10;  IL11;  OSM;  PGF;  IL23A;  TGFB3;  TGFB2;  IL17A;  TNF;  IL3;  CSF2;  FIGF;  CSF1;  CCL5;  IL5;  IL4;  IFNA7;  TNFSF8;  LTB;  IFNA2;  FASLG;  VEGFC;  VEGFB;  VEGFA;  IL24;  EGF;  
Prostate cancer PDGFRB;  FRAP1;  CCND1;  CHUK;  PIK3CG;  PIK3R1;  PDGFB;  PDGFA;  INS;  HSP90AA1;  MAP2K1;  RELA;  TGFA;  PTEN;  IKBKB;  GRB2;  RB1;  EP300;  ARAF;  AR;  IKBKG;  AKT1;  IGF1R;  GSK3B;  BRAF;  HRAS;  EGFR;  RAF1;  EGF;  CTNNB1;  NFKB2;  NFKBIA;  MAP2K2;  CDKN1B;  CDKN1A;  MAPK3;  CASP9;  SOS1;  AKT2;  KRAS;  CREB1;  CREBBP;  ERBB2;  
Pancreatic cancer TGFBR1;  CCND1;  CHUK;  SMAD2;  SMAD4;  PIK3CG;  PIK3R1;  MAP2K1;  MAPK9;  RAC1;  TGFA;  IKBKB;  RB1;  RALGDS;  ARAF;  VEGFB;  IKBKG;  AKT1;  AKT2;  BRAF;  EGFR;  RAF1;  EGF;  TGFB3;  TGFB2;  NFKB2;  FIGF;  PGF;  MAPK3;  CASP9;  MAPK8;  CDKN2A;  VEGFC;  KRAS;  VEGFA;  RELA;  ERBB2;  TGFB1;  
Toll-like receptor signaling pathway IL12B;  IL12A;  CHUK;  PIK3CG;  PIK3R1;  MAP2K2;  MAP2K1;  IFNA16;  MAPK9;  JUN;  MYD88;  TLR1;  TLR2;  IFNB1;  IKBKB;  CCL3;  MAP2K4;  TLR3;  RIPK1;  IKBKG;  IRF3;  AKT1;  IFNA1;  FADD;  AKT2;  CD40;  TICAM1;  MAP3K7;  MAPK3;  TNF;  NFKB2;  NFKBIA;  RAC1;  MAPK14;  CASP8;  CCL4;  MAPK8;  IFNA7;  IL6;  IFNA2;  FOS;  TLR8;  RELA;  
T cell receptor signaling pathway CHUK;  PIK3CG;  PIK3R1;  NCK2;  CD28;  NFKB2;  CD40LG;  NCK1;  AKT1;  IKBKB;  GRB2;  NFATC1;  IFNG;  IL2;  VAV2;  NFKBIA;  IKBKG;  IL10;  AKT2;  ICOS;  LCK;  HRAS;  NFATC2;  RHOA;  JUN;  TNF;  MAP3K14;  PTPN6;  NFKBIB;  CSF2;  IL5;  IL4;  SOS1;  CBL;  KRAS;  CD4;  FOS;  CD8A;  FYN;  
MAPK signaling pathway CHUK;  AKT1;  PDGFB;  PDGFA;  MAP2K2;  MAP2K1;  EGFR;  MAPK9;  JUN;  GSTM3;  GSTM2;  HSPA1B;  GSTM1;  HSPA1A;  TNFRSF1A;  CASP3;  IL1A;  IKBKB;  FASLG;  MAP2K4;  TGFB2;  NFKB2;  RASA1;  CRK;  FGF2;  IKBKG;  MAP3K5;  GSTA1;  AKT2;  BRAF;  HRAS;  MAP3K7;  RAF1;  EGF;  TGFB3;  MYC;  GSTZ1;  MAPK14;  TNF;  JUND;  GSTP1;  MAP3K14;  GSTT1;  IL1R1;  MAPK3;  PRKCA;  MAPK8;  NTRK1;  SOS1;  GRB2;  IL1R2;  GSTO2;  ELK1;  RPS6KA1;  FAS;  RPS6KA3;  KRAS;  FOS;  ATF2;  RAC1;  TRAF2;  TGFB1;  
Chronic myeloid leukemia CCND1;  CHUK;  SMAD4;  PIK3CG;  PIK3R1;  MAP2K2;  MAP2K1;  ABL1;  IKBKB;  GRB2;  SHC1;  RB1;  ARAF;  IKBKG;  AKT1;  AKT2;  CRK;  BRAF;  TGFBR1;  RAF1;  TGFB1;  TGFB3;  MYC;  NFKB2;  NFKBIA;  CDKN1A;  MAPK3;  SOS1;  CDKN2A;  CBL;  KRAS;  HRAS;  TGFB2;  RELA;  
Colorectal cancer PDGFRB;  CCND1;  SMAD2;  SMAD4;  PIK3CG;  PIK3R1;  MAP2K1;  MAPK9;  JUN;  CASP3;  GRB2;  RALGDS;  ARAF;  AKT1;  BAX;  IGF1R;  GSK3B;  BRAF;  EGFR;  RAF1;  TGFB1;  TGFB3;  MYC;  CTNNB1;  MET;  RHOA;  MAPK3;  CASP9;  MAPK8;  SOS1;  AKT2;  TGFBR1;  KRAS;  FOS;  TGFB2;  RAC1;  
Antigen processing and presentation KIR2DL3;  KIR2DS2;  KIR2DS1;  KIR2DL2;  KIR2DL1;  HSP90AA1;  TAP1;  HSPA1B;  HSPA1A;  IFNA1;  HLA-DMA;  CD74;  HLA-DRA;  HLA-DRB1;  HLA-B;  HLA-C;  HLA-DRB4;  HLA-DRB5;  HLA-DRB3;  CTSB;  KIR3DL1;  B2M;  HLA-E;  HLA-DMB;  TAP2;  IFNA16;  HLA-DQB1;  HLA-DQA2;  HLA-DQA1;  IFNA7;  LTA;  IFNA2;  HLA-A;  CD4;  CREB1;  CD8A;  
Focal adhesion PDGFRB;  CCND1;  PIK3CG;  PIK3R1;  PDGFB;  PDGFA;  MAP2K1;  ITGA5;  MAPK9;  PTK2;  JUN;  ITGA3;  FLT1;  FLT4;  ITGB3;  KDR;  THBS1;  VAV2;  AKT2;  CRK;  AKT1;  IGF1R;  ITGB1;  GSK3B;  PTEN;  BRAF;  EGFR;  RAF1;  EGF;  RHOA;  CTNNB1;  SRC;  MET;  FIGF;  PGF;  MAPK3;  FN1;  PRKCA;  MAPK8;  SOS1;  SHC1;  ITGAV;  ELK1;  GRB2;  VEGFC;  VEGFB;  VEGFA;  HRAS;  RAC1;  ERBB2;  FYN;  
Renal cell carcinoma PIK3CG;  PIK3R1;  MAP2K2;  MAP2K1;  RAC1;  TGFA;  GRB2;  GAB1;  EPAS1;  EP300;  ARAF;  VEGFB;  AKT1;  AKT2;  CRK;  BRAF;  RAF1;  TGFB1;  TGFB3;  TGFB2;  JUN;  MET;  VEGFC;  FIGF;  PGF;  MAPK3;  SOS1;  HIF1A;  KRAS;  VEGFA;  HRAS;  CREBBP;  
Bladder cancer CCND1;  MAP2K2;  MAP2K1;  TYMP;  PGF;  RB1;  ARAF;  VEGFB;  MMP1;  MMP2;  MMP9;  CDH1;  BRAF;  EGFR;  RAF1;  EGF;  MYC;  FIGF;  CDKN1A;  MAPK3;  CDKN2A;  VEGFC;  KRAS;  VEGFA;  HRAS;  ERBB2;  
Glioma PDGFRB;  FRAP1;  CCND1;  SHC1;  PIK3CG;  PIK3R1;  PDGFB;  PDGFA;  MAP2K2;  MAP2K1;  PLCG1;  TGFA;  PTEN;  GRB2;  RB1;  AKT2;  AKT1;  IGF1R;  ARAF;  BRAF;  EGFR;  RAF1;  EGF;  CDKN1A;  MAPK3;  PRKCA;  SOS1;  CDKN2A;  KRAS;  HRAS;  
Type I diabetes mellitus IL12B;  IL12A;  INS;  LTA;  GZMB;  IL2;  HLA-DMA;  IL1A;  HLA-DRA;  HLA-DRB1;  IFNG;  HLA-C;  HLA-DRB4;  HLA-DRB5;  HLA-DRB3;  HLA-E;  TNF;  HLA-DMB;  HLA-DQB1;  HLA-DQA2;  HLA-DQA1;  CD28;  FASLG;  FAS;  HLA-A;  HLA-B;  
Endometrial cancer CCND1;  PIK3CG;  PIK3R1;  MAP2K2;  MAP2K1;  GSK3B;  PTEN;  GRB2;  ARAF;  AKT1;  AKT2;  CDH1;  BRAF;  EGFR;  RAF1;  EGF;  MYC;  CTNNB1;  MAPK3;  CASP9;  SOS1;  ELK1;  KRAS;  HRAS;  ERBB2;  
Fc epsilon RI signaling pathway IL13;  PIK3CG;  PIK3R1;  MAP2K2;  MAP2K1;  PLCG1;  LYN;  MS4A2;  GRB2;  MAP2K4;  VAV2;  AKT1;  AKT2;  HRAS;  RAF1;  MAPK3;  TNF;  IL3;  CSF2;  MAPK14;  IL5;  IL4;  MAPK8;  SOS1;  KRAS;  MAPK9;  RAC1;  FYN;  
Apoptosis CHUK;  PIK3CG;  PIK3R1;  TNFRSF1A;  MYD88;  IL1R1;  CASP3;  IL1A;  IKBKB;  NFKB2;  TRADD;  RIPK1;  IKBKG;  AKT1;  BAX;  FADD;  AKT2;  IRAK3;  TNF;  MAP3K14;  NFKBIA;  TNFRSF10A;  IL3;  CASP9;  CASP8;  NTRK1;  FASLG;  FAS;  RELA;  TRAF2;  
Non-small cell lung cancer CCND1;  PIK3CG;  PIK3R1;  MAP2K2;  MAP2K1;  PLCG1;  TGFA;  GRB2;  RB1;  ARAF;  AKT1;  AKT2;  BRAF;  EGFR;  HRAS;  EGF;  MAPK3;  CASP9;  PRKCA;  SOS1;  CDKN2A;  KRAS;  RAF1;  ERBB2;  
Melanoma PDGFRB;  CCND1;  PIK3CG;  PIK3R1;  PDGFB;  PDGFA;  MAP2K2;  MAP2K1;  PTEN;  RB1;  AKT2;  FGF2;  AKT1;  IGF1R;  ARAF;  CDH1;  BRAF;  EGFR;  RAF1;  EGF;  MET;  CDKN1A;  MAPK3;  CDKN2A;  KRAS;  HRAS;  
Epithelial cell signaling in Helicobacter pylori infection HBEGF;  CHUK;  MAPK9;  RELA;  CASP3;  LYN;  IKBKB;  MAP2K4;  MAP3K14;  CSK;  IKBKG;  NOD1;  EGFR;  ADAM17;  ADAM10;  JUN;  SRC;  MET;  NFKB2;  NFKBIA;  TJP1;  MAPK14;  MAPK8;  PLCG1;  RAC1;  
Acute myeloid leukemia FRAP1;  CCND1;  CHUK;  PIK3CG;  PIK3R1;  MAP2K2;  MAP2K1;  IKBKB;  GRB2;  ARAF;  IKBKG;  AKT1;  AKT2;  BRAF;  RAF1;  MYC;  NFKB2;  MAPK3;  SOS1;  KRAS;  HRAS;  RELA;  
Adipocytokine signaling pathway FRAP1;  JAK1;  CHUK;  JAK2;  MAPK9;  TNFRSF1B;  TNFRSF1A;  IKBKB;  TRADD;  IKBKG;  IRS1;  AKT1;  AKT2;  TNF;  SOCS3;  NFKB2;  NFKBIA;  NFKBIB;  MAPK8;  ADIPOQ;  RELA;  TRAF2;  
Hematopoietic cell lineage IL1R2;  ITGA3;  IL1R1;  IL1A;  EPO;  ITGB3;  FCGR1A;  IL6R;  IL2RA;  IL11;  IL4R;  TNF;  IL3;  CSF2;  CSF1;  CD44;  IL5;  IL4;  IL6;  ITGA5;  CD9;  CD4;  CD8A;  
B cell receptor signaling pathway AKT1;  IKBKG;  CHUK;  IKBKB;  NFATC1;  AKT2;  PIK3CG;  PIK3R1;  GSK3B;  HRAS;  VAV2;  KRAS;  NFATC2;  NFKBIB;  JUN;  NFKBIA;  FOS;  RAC1;  NFKB2;  PTPN6;  LYN;  
Jak-STAT signaling pathway JAK2;  SOS1;  STAT6;  AKT1;  GRB2;  AKT2;  PIK3CG;  PIK3R1;  STAT1;  STAM2;  MYC;  JAK1;  EP300;  CBL;  STAT5B;  CCND1;  CREBBP;  SOCS3;  STAM;  
Adherens junction INSR;  TGFBR1;  TJP1;  MAPK3;  RAC1;  SMAD2;  SMAD4;  RHOA;  CDH1;  ERBB2;  EGFR;  MAP3K7;  EP300;  PTPN6;  IGF1R;  CTNNB1;  PTPN1;  CREBBP;  MET;  SRC;  FYN;  
Insulin signaling pathway FRAP1;  PIK3CG;  PIK3R1;  INS;  MAP2K2;  MAP2K1;  MAPK9;  IKBKB;  GRB2;  SOCS3;  ARAF;  IRS1;  AKT1;  AKT2;  CRK;  GSK3B;  BRAF;  RAF1;  PTPN1;  INSR;  MAPK3;  MAPK8;  SOS1;  SHC1;  CBL;  ELK1;  KRAS;  HRAS;  
VEGF signaling pathway MAPK3;  MAPK14;  CASP9;  AKT1;  PRKCA;  NFATC1;  AKT2;  PIK3CG;  PIK3R1;  KDR;  MAP2K2;  KRAS;  PLCG1;  NFATC2;  HRAS;  PTK2;  MAP2K1;  RAF1;  SRC;  RAC1;  
Protein kinases PDGFRB;  FRAP1;  JAK1;  CHUK;  JAK2;  BMX;  MAP2K2;  MAP2K1;  EGFR;  MAPK9;  PTK2;  TGFBR1;  ABL1;  FLT1;  ABL2;  LYN;  IKBKB;  FLT4;  INSR;  MAP2K4;  KDR;  RIPK2;  CSK;  ARAF;  RIPK1;  IKBKG;  MAP3K5;  AKT1;  PRKD1;  IGF1R;  GSK3B;  LCK;  IRAK3;  MAP3K7;  RAF1;  RIPK3;  PTK2B;  MAPK3;  SRC;  HCK;  MET;  MAP3K14;  CDK9;  MAPK14;  PRKCD;  PRKCA;  MAPK8;  PRKDC;  NTRK1;  RPS6KA1;  AKT2;  RPS6KA3;  ERBB4;  BRAF;  ERBB2;  ERBB3;  FYN;  
Small cell lung cancer IKBKG;  PTEN;  ITGB1;  CCND1;  CHUK;  IKBKB;  AKT2;  PIK3CG;  PIK3R1;  ITGA3;  ITGAV;  RB1;  MYC;  NFKBIA;  FN1;  PTK2;  AKT1;  RELA;  NFKB2;  TRAF2;  CASP9;  
mTOR signaling pathway FRAP1;  PIK3R1;  MAPK3;  AKT1;  HIF1A;  AKT2;  PIK3CG;  RPS6KA3;  FIGF;  INS;  BRAF;  RPS6KA1;  VEGFC;  VEGFB;  VEGFA;  PGF;  
Regulation of actin cytoskeleton PDGFRB;  BDKRB2;  PIK3CG;  PIK3R1;  PDGFB;  PDGFA;  INS;  MAP2K2;  MAP2K1;  ITGA5;  PTK2;  ITGA3;  ITGB3;  VAV2;  CSK;  ARAF;  FGF2;  PIP4K2B;  CRK;  BRAF;  EGFR;  RAF1;  EGF;  RHOA;  ITGB1;  MAPK3;  FN1;  SOS1;  ITGAV;  KRAS;  HRAS;  RAC1;  
GnRH signaling pathway MAP2K2;  MAP2K4;  MAPK14;  PTK2B;  MAP2K1;  MAPK8;  MMP14;  SOS1;  MMP2;  ELK1;  KRAS;  MAPK9;  EGFR;  RAF1;  HBEGF;  HRAS;  JUN;  GRB2;  MAPK3;  SRC;  
TGF-beta signaling pathway SMAD7;  TGFBR1;  MAPK3;  TGFB3;  ID1;  SMAD2;  SMAD4;  IFNG;  RHOA;  THBS1;  BMP7;  EP300;  TGFB1;  BMP2;  MYC;  DCN;  TNF;  CREBBP;  TGFB2;  
Metabolism of xenobiotics by cytochrome P450 CYP1A2;  EPHX1;  CYP2B6;  GSTA1;  CYP2C19;  CYP3A5;  GSTO2;  GSTZ1;  CYP1B1;  CYP2C8;  GSTM3;  GSTM2;  CYP2E1;  GSTM1;  GSTP1;  CYP3A4;  GSTT1;  
Type II diabetes mellitus FRAP1;  MAPK3;  IKBKB;  MAPK8;  ADIPOQ;  PIK3CG;  PIK3R1;  IRS1;  INS;  MAPK9;  SOCS3;  TNF;  INSR;  
Cell adhesion molecules (CAMs) PDGFRB;  ITGA5;  ITGAV;  ITGA3;  CD40LG;  CD40;  HLA-DMA;  HLA-DMB;  HLA-DRA;  HLA-DRB1;  HLA-B;  HLA-C;  HLA-DRB4;  HLA-DRB5;  HLA-DRB3;  VCAM1;  NRP1;  ICOS;  CDH1;  SELE;  HLA-E;  SELP;  ITGB1;  CD44;  HLA-DQB1;  HLA-DQA2;  HLA-DQA1;  CD28;  ITGB3;  HLA-A;  CD4;  OCLN;  CD8A;  
Thyroid Cancer CCND1;  MAPK3;  NTRK1;  CDH1;  BRAF;  MAP2K2;  MAP2K1;  KRAS;  HRAS;  MYC;  CTNNB1;  
Progesterone-mediated oocyte maturation MAPK14;  AKT1;  MAP2K1;  MAPK8;  IGF1R;  PIK3CG;  PIK3R1;  PGR;  AKT2;  INS;  BRAF;  HSP90AA1;  RPS6KA1;  KRAS;  RPS6KA3;  RAF1;  ARAF;  MAPK3;  MAPK9;  
CAM ligands PDGFB;  PDGFA;  THBS1;  FGB;  FGF2;  FGG;  MMP1;  MMP2;  C3;  LCK;  CTGF;  ADAM17;  TGFB1;  TGFB3;  TGFB2;  FIGF;  PGF;  FN1;  VEGFC;  VEGFB;  VEGFA;  FYN;  
Complement and coagulation cascades C4A;  BDKRB2;  C1QC;  C1QB;  C1QA;  CD46;  FGB;  CFH;  F3;  C4B;  SERPINE1;  C3;  FGG;  PLAU;  
Leukocyte transendothelial migration CXCR4;  MMP2;  MAPK14;  PRKCA;  MMP9;  PIK3CG;  PIK3R1;  CXCL12;  VCAM1;  VAV2;  ITGB1;  PLCG1;  PTK2B;  PTK2;  CTNNB1;  OCLN;  RAC1;  RHOA;  
Renin - angiotensin system ACE;  CMA1;  AGT;  ACE2;  AGTR2;  AGTR1;  REN;  
Gap junction PDGFRB;  TJP1;  MAPK3;  PRKCA;  SOS1;  PDGFB;  PDGFA;  MAP2K2;  MAP2K1;  EGFR;  RAF1;  EGF;  HRAS;  GRB2;  KRAS;  SRC;  
Long-term potentiation MAPK3;  PRKCA;  EP300;  BRAF;  MAP2K2;  RPS6KA1;  RPS6KA3;  RAF1;  HRAS;  ARAF;  MAP2K1;  KRAS;  CREBBP;  
Axon guidance ABL1;  ITGB1;  MAPK3;  NCK1;  NFATC1;  NRP1;  RHOA;  GSK3B;  CXCR4;  HRAS;  KRAS;  RASA1;  PTK2;  NCK2;  RAC1;  MET;  FYN;  NFATC2;  
Glutathione metabolism GPX1;  GSTA1;  GSTO2;  GSTZ1;  GSTM3;  GSTM2;  GSTM1;  GSTP1;  GSTT1;  
Dorso-ventral axis formation MAPK3;  GRB2;  SOS1;  MAP2K1;  EGFR;  KRAS;  ETS1;  
Wnt signaling pathway RAC1;  CCND1;  NFATC1;  JUN;  SMAD2;  MAPK8;  SMAD4;  PRKCA;  GSK3B;  MMP7;  FOSL1;  MAPK9;  MAP3K7;  EP300;  NFATC2;  MYC;  CTNNB1;  CREBBP;  RHOA;  
Cell cycle PRKDC;  ABL1;  CDKN1B;  CDKN1A;  CCND1;  SMAD2;  SMAD4;  CDKN2A;  RB1;  BUB3;  EP300;  TGFB1;  TGFB3;  TGFB2;  CREBBP;  GSK3B;  
Cytochrome P450 CYP1A2;  CYP1B1;  CYP2B6;  CYP2C19;  CYP2C8;  CYP19A1;  CYP11B2;  CYP2E1;  CYP3A5;  CYP3A4;  
Huntington's disease CASP3;  CASP8;  CASP1;  GRB2;  EP300;  RASA1;  CREBBP;  
Dentatorubropallidoluysian atrophy (DRPLA) INSR;  INS;  CASP3;  CASP1;  CASP8;  
Long-term depression MAPK3;  LYN;  PRKCA;  IGF1R;  BRAF;  MAP2K2;  MAP2K1;  KRAS;  HRAS;  ARAF;  RAF1;  
p53 signaling pathway PTEN;  CDKN1A;  CASP3;  CASP9;  CASP8;  BAX;  CDKN2A;  FAS;  SERPINE1;  CCND1;  
Linoleic acid metabolism CYP1A2;  CYP2C19;  CYP2C8;  CYP2E1;  CYP3A5;  CYP3A4;  
Melanogenesis MAPK3;  PRKCA;  EP300;  GSK3B;  MAP2K2;  KRAS;  RAF1;  HRAS;  CTNNB1;  MAP2K1;  CREB1;  CREBBP;  
Caffeine metabolism NAT1;  NAT2;  CYP1A2;  
Regulation of autophagy IFNA1;  IFNA16;  IFNA7;  IFNG;  IFNA2;  INS;  
Trinitrotoluene degradation NAT1;  NAT2;  

Creative Commons License
© 2008-2010, Bio-X Center | Fudan University | Chinese Academy of Sciences | Shanghai Jiao Tong University
Recommended browsers: FireFox 3 or Internet Explorer 7, resolution: 1280*1024 or higher